Ontology highlight
ABSTRACT: Significance
MDS are myeloid clonal hemopathies with a low 5-year survival rate, and approximately half of the cases do not respond to standard HMA therapy. Our innovative single-cell multiomics approach offers valuable biological insights and potential biomarkers associated with the demethylating agent efficacy. It also identifies vulnerabilities that can be targeted using personalized combinations of small drugs and antibodies.
SUBMITTER: Campillo-Marcos I
PROVIDER: S-EPMC10860538 | biostudies-literature | 2024 Feb
REPOSITORIES: biostudies-literature
Campillo-Marcos Ignacio I Casado-Pelaez Marta M Davalos Veronica V Ferrer Gerardo G Mata Caterina C Mereu Elisabetta E Roué Gael G Valcárcel David D Molero Antonieta A Zamora Lurdes L Xicoy Blanca B Palomo Laura L Acha Pamela P Manzanares Ana A Tobiasson Magnus M Hellström-Lindberg Eva E Solé Francesc F Esteller Manel M
Cancer research communications 20240201 2
Alterations in epigenetic marks, such as DNA methylation, represent a hallmark of cancer that has been successfully exploited for therapy in myeloid malignancies. Hypomethylating agents (HMA), such as azacitidine, have become standard-of-care therapy to treat myelodysplastic syndromes (MDS), myeloid neoplasms that can evolve into acute myeloid leukemia. However, our capacity to identify who will respond to HMAs, and the duration of response, remains limited. To shed light on this question, we ha ...[more]